STADA Romania announces consolidated turnover of 247 million RON, up 37 percent in 2022
STADA Romania, the Romanian subsidiary of the German group STADA Arzneimittel AG, announces for 2022 a consolidated business value of more than RON 247 million, up 37 percent compared to 2021, when it generated business of RON 180.1 million.
STADA Group operates on the Romanian market through STADA M&D (pharmaceutical sales operations) and STADA Hemofarm (pharmaceutical testing laboratory and quality auditing).
STADA M&D estimates business of RON 188.8 million in 2022, up 32 percent as compared to the previous year. The results are unaudited and represent, for the first time, cumulative reporting with sales of SC Walmark SRL, after the completion of the local takeover of the entity. Walmark was globally acquired by STADA Group at the end of 2019.
The increase in business is due, on the one hand, to the development of the Speciality product portfolio with biosimilar and generic molecules registered on the Romanian market for new therapeutic areas such as oncology, rheumatology, haematology, as well as new innovative device-assisted therapies for the treatment of Parkinson’s disease (Lecigon and APO-go). The increase in turnover is also due to the performance of products in the Consumer Health Care portfolio (OTC and dietary supplements), which remain at the top of Romanians’ preferences for various conditions (Urinal, Hepathrombin and Minimartienii being leading brands in their categories).
In Romania, STADA M&D operates marketing and sales activities from its headquarters in Bucharest, a logistic hub in Timisoara, where it has a 5,000-pallet warehouse, and in 2022, it started building a production facility located in Arieș Industrial Park in Turda, Cluj County.
The greenfield project has an investment value of more than EUR 50 million, an area of 30,000 sqm, and it is partially supported in its implementation by the Romanian Government through a state aid contribution of approximately EUR 20 million. Currently, the team consists in 208 employees in the 3 operational centres, with the team in Turda expected to grow to more than 370 new employees upon completion of the project in October 2024.
The new production and packaging facility will initially comprise 9 state-of-the-art technology lines for solid dosage products (capsules and tablets), with a capacity of 120 million boxes of pharmaceutical product per year. The total surface area of the unit is approximately 30,000 sqm, and it allows for a rapid expansion of the production lines up to 12.
The entire surface of the acquired land is of 100,000 sqm, and it also allows for further development of the production facilities through the construction of new buildings, depending on market demand and in relation to the ongoing development needs of the company.
The finished products from Turda facility – both prescription and over-the-counter pharmaceuticals – are intended to serve mainly Romania and the European markets where STADA Group operates.
STADA Hemofarm ended 2022 with a turnover of RON 58.2 million, an increase of 63 percent compared to 2021, and carried out a total of 8,945 product series tests, covering all forms of medicine: capsules, ointment, syrup, creams, injectables, tablets, spray etc. STADA Hemofarm laboratory is located in Timisoara, where the logistic centre is also located, and it is the most modern and complex STADA laboratory in the European Union, equipped with state-of-the-art equipment. By 2023, the Romanian entity plans to invest EUR 2 million to expand the unit and increase the number of tests to 13,000. STADA Hemofarm currently employs 172 specialists.
Leave a Reply